Fidelity SPDR Advertisement
Home > Boards > US OTC > Food - Beverages >

MusclePharm Corporation (MSLP)

MSLP RSS Feed
Add MSLP Price Alert      Hide Sticky   Hide Intro
Moderator: No Moderator Neuronal, drive929, bajista, basebalplayr33
Search This Board:
Last Post: 11/22/2014 9:30:35 PM - Followers: 384 - Board type: Free - Posts Today: 4






4721 Ironton Street
Building A
Denver, CO 80239
Website: http://www.musclepharm.com
Twitter: https://twitter.com/#!/MusclePharm
Facebook: http://www.facebook.com/MusclePharm
Phone: 303-396-6100
Email: info@musclepharm.com
 

Investor Kit: http://www.qualitystocks.net/content/clients/mslp-summary.pdf
 

MusclePharm News and Updates

(OTC QB: MSLP) MusclePharm: Money Report Interview of CEO Brad Pyatt (Fox Business)

See Dave Gentry's interview of CEO Brad Pyatt's on "The RedChip Money Report."

MusclePharm Muscling in On the Big Boys - A MUST Read About MusclePharm's 2013 Projections


Reuters.com: MusclePharm Corp Completes $12 Million Offering of Series D Convertible Stock


MusclePharm Corp announced that it has successfully completed the final closing of a $12.0 million registered direct offering of its Series D Convertible Preferred Stock. The Frost Group, LLC, headed by Miami entrepreneur Dr. Phillip Frost, was the lead investor in the offering and elected to increase its previously announced investment in the offering to a total of $2.9 million dollars. MusclePharm issued a total of 1,500,000 shares of its Series D Convertible Preferred Stock in a registered direct offering at a price of $8.00 per share. Each share of Series D Convertible Preferred Stock is convertible into two shares of common stock, subject to adjustment. The net proceeds to MusclePharm from the closings were approximately $10.8 million after deducting placement agent fees and offering expenses. GVC Capital LLC acted as the lead placement agent for this offering.

MusclePharm's CEO Letter to Shareholders Carried by NBC

Forbes Magazine: Billionaire Pharmaceutical Entrepreneur Makes Bet On Fast Growing Supplement Manufacturer: MusclePharm

SeekingAlpha.com: Some Thoughts On MusclePharm CEO's Letter To Shareholders

Yahoo! Finance: Manager of Royce Funds to Appear on This Week's "The RedChip Money Report"


Announcement of CEO Brad Pyatt's appearance is also made in this press release.

MusclePharm CEO Issues Letter to Shareholders

DENVER, CO, Feb 15, 2013 (MARKETWIRE via COMTEX) -- MusclePharm Corporation (OTCQB: MSLP), a nutritional supplement company focused on active lifestyles, is pleased to announce that it has released a letter from its CEO, Bradley J. Pyatt, to update shareholders on the current status of the Company.

Dear Valued MusclePharm Shareholders,

I want to personally thank you for being a MusclePharm Corporation shareholder. We are excited about the future of our Company and this letter outlines our vision and plans for the future.

Over the past three years we achieved exponential product sales growth, growing from around $1.4 million in revenue for 2009, to approximately $78 million in 2012. However, to finance that growth from essentially a startup mode we had to utilize dilutive financing instruments, which were very expensive and hurt our financial performance, and as one would expect, our stock price suffered too. All of us at MusclePharm believe that our market capitalization today is not a valid reflection of our Company's current underlying fundamentals. Below I address how we are proactively addressing our future, which we believe should result in better financial results and a higher stock price as we move forward.

As you probably know, we recently completed a $12.0 million registered direct offering of our Series D Convertible Preferred Stock at $8.00 per share. Each preferred share is convertible into two shares of our common stock. In 2012, we spent considerable time cleaning up the Company's balance sheet and raising other capital to support our growth. In late 2012, we issued 516,308 shares of our common stock to several accredited investors pursuant to conversions of warrants to purchase an aggregate of 728,648 shares of our common stock. As a result of these warrant conversions and other extinguishments of derivative liabilities, our stockholders' deficit decreased from approximately $11.0 million at June 30, 2012 to approximately $7.3 million at September 30, 2012 and our derivative liabilities decreased from approximately $7.9 million at June 30, 2012 to approximately $25,000 at September 30, 2012. Now, in the first quarter of 2013, after our registered direct offering, we believe we have positioned the Company to continue growing with the proper type of capital structure that will allow us to focus on profitability.

With the proceeds from our recently completed offering we paid off all our mezzanine and short-term debt. We are now debt free. We expect to use the remaining proceeds from the offering to launch new products, seek to expand internationally, and seek to increase our U.S. sales force.

As you also are probably aware, in late 2012 we completed an 850:1 reverse stock split. The reverse split was a necessary step for us to seek a listing on a stock exchange. We expect we will have such a listing this summer after we post our 2013 first quarter results. There are several benefits to being listed on a stock exchange, but the most important is the ability to seek institutional investment in our shares. The institutions that were looking at investing in our Company over the past few years declined for the most part, citing our lack of a stock exchange listing. Going forward, these investors will have the ability to participate in our Company once we are listed on an exchange.

Our Growth Story

In September of 2008, we started MusclePharm out of my garage in Denver, Colorado. Fast-forward to today and we are recognized as a global leader in a multi-billion dollar industry. Our gross revenue increased exponentially as follows*:

Dollars in millions 2009: $0 - $1 2010: $1 - 4 (300% gain YOY) 2011: $4 - 17 (325% gain YOY) 2012: $17 - 78 (370% gain YOY)

* These numbers have been rounded for ease of reading, and 2012 is unaudited.

In a time when our economy has struggled, we achieved revenue growth of approximately 300%+ year over year. We project we will increase our gross revenues in 2013 to over $100 million.

At the 2012 Bodybuilding.com Supplement Awards, we received three Awards of Excellence; we received (i) the "Brand of the Year" award, (ii) the "Packaging of the Year" award, and (iii) the "Pre-Workout Supplement of the Year" award for Assault(TM). On top of that, we've won over 15 other industry awards since our inception.

Our headquarters in Denver, Colorado has a state-of-the-art over 30,300 square feet athletic facility with a medical and clinical testing department, complete with equipment for measuring and conducting athletic clinical studies and supporting athletes. Our medical and clinical professionals consist of several nationally recognized medical doctors and nutritional experts who oversee our product research, formulation, efficacy analysis and testing. It also serves as a place for some of the world's top athletes to come and train and be educated on the latest nutritional advancements that we have under development.

Our primary growth strategy is to:

-- Increase our product distribution and sales through increased market penetrations both domestically and internationally;

-- Increase our margins by focusing on streamlining our operations and seeking operating efficiencies in all areas of our operations;

-- Continue to conduct additional testing of the safety and efficacy of our products and formulate new products; and

-- Increase awareness of our products by increasing our marketing and branding opportunities through endorsements, sponsorships and brand extensions.

Our core marketing strategy is to brand MusclePharm as the "must have" fitness brand for workout enthusiasts and elite athletes. We seek to be known as the "athlete's company," run by athletes who create their products for other athletes, both professional and otherwise. We believe that our marketing mix of endorsers, sponsorships and providing sample products for our retail resellers to use is an optimal strategy to increase sales.

In addition:

-- Our products are currently sold in over 110 countries, with the goal of reaching 175 countries in the next few years.

-- Our products are available in over 10,500 U.S. retail outlets with the goal of reaching 20,000+ in the next few years.

-- Retail stores include GNC and Vitamin Shoppe, as well as over 100 online stores, including Bodybuilding.com, Vitacost.com, GNC.com,Amazon.com, SupplementWarehouse.com, AllStarHealth.com, LuckyVitamin.com, Dick's Sporting Goods, and many more

We recently renegotiated our terms with our manufacturers and have refined our distribution model, and as a result, we should experience better sales margins. On top of this, we have reviewed our operating costs and are cutting several non- essential expenses. We also recently launched a new product called Amino1. To date, it is the fastest growing product (sku) we have ever had here at MusclePharm.

Finally, in mid 2012, we hired an experienced CFO, Gary Davis, who most recently served as executive vice president and CFO for Bodybuilding.com for almost six years. Bodybuilding.com is a world leader in sports fitness and nutritional supplements and is a very large website for nutritional products. Gary's experience includes extensive experience as a chief financial officer with strengths in external and management reporting and analysis, accounting, tax, treasury, human resources and risk management functions in public and private companies along with the dietary supplement industry. He provides strength and direction for the demands and growth of MusclePharm.

Going from no revenues to over $78 million in less than four years was impressive growth, but all of us here at MusclePharm have the goal of reaching $500 million in annual sales -- but only at a profitable level. We are excited about focusing on our core business without the after effects of burdensome financings.

If you have any questions regarding our Company, please feel free to contact me directly or our office at the numbers listed below.

Sincerely,

Brad Pyatt
Chief Executive Officer


Contact:
MusclePharm Investor

Alex Partners, LLC
Scott Wilfong
President
Telephone: 425-242-0891
Email

 

Opko's Billionaire CEO Invests In MusclePharm

Read John H. Ford's thoughts on current investment strategies.

MusclePharm Reports Revenue Growth

MusclePharm Corp. (MSLP) is a healthy life-style company focused on developing and manufacturing a full line of National Science Foundation approved nutritional supplements that do not use any substances banned in the sports industry. The company continues to expand rapidly, with revenues growing from $80,739 in 2008, $1,016,000 in 2009, and $4,076,764 in 2010 to $3,517,774 for just the first quarter of 2011.

Net sales for the first three months of 2012 increased nearly four-fold to approximately $19 million, up from $4 million for Q1 2011. The company's international sales grew to approximately $4 million from $1 million in Q1 2011. There were general and administrative expenses of approximately $5 million, or 26 percent of net sales, compared with $2 million, or 50 percent of net sales for the same quarter last year. The company's income from operations increased to approximately $1 million, compared to a similar loss of $1 million for Q1 2011. Its 2012 revenues for 2012 - as of Q3 2012 - are approximately $51 million.

MusclePharm is expected to exceed previous revenues, with numbers in the $100 million for 2013 likely. Its debt levels and profit margins have had some issues, mainly because due to the company's young age and sales volumes. However, these have been eliminated and the profit margins are anticipated to turn positive. The increase in sales volumes are expected to grow with the company's lower manufacturing costs.

MusclePharm's revenues stand as follows:

o 2009 revenues: $1 million
o 2010 revenues: $4.1 million
o 2011 revenues: $17 million
o 2012 revenues: $51 million (as of the third quarter)

Current CEO Brad Pyatt founded the company to develop a superior line of nutritional supplements that would help fellow athletes improve their performance in a way that existing supplements did not. Even as the company has grown, its mission has remained the same: to improve its customers' lives, increase their ability to excel, use cutting-edge science to develop the best nutritional supplements on the market and provide a safe option for athletes.

Now sold in more than 120 countries and available in over 5,000 U.S. retail outlets, including GNC and Vitamin Shoppe locations, the company's products address all categories of an active lifestyle, including muscle building, weight loss, and maintaining general fitness through a daily nutritional supplement regimen. The products are also sold in over 100 online stores, including BodyBuilding.com, Amazon.com and Vitacost.com.

Over the last few years, the consumption of sports nutrition products has shifted to mainstream consumers who have become the key drivers of growth within the industry. According to BCC Research, the U.S. is the largest consumer market for sports nutrition products, with annual sales reaching $22 billion in 2007, and projected sales of $29 billion in 2013. With a full line of supplements and an extensive distribution network, MusclePharm is well positioned to capitalize on the growing demand.

News: http://finance.yahoo.com/q/h?s=MSLP.OB
SEC Filings: http://www.sec.gov/cgi-bin/browse-edgar?company=musclepharm
 

MusclePharm Reviewed: MusclePharm Seeks NASDAQ Listing, Eliminates Debt, Grows Q3 Revenues by $14M YoY

Next year will be pivotal for MusclePharm. The company is nearing the $100 million threshold of annual sales, its brand has broad acceptance in the sports community, and it has a large distribution network of major domestic and international stores. Now that the company has cleaned its balance sheet by eliminating toxic financing, shareholders will expect market capitalization to better reflect sales numbers. A possible NASDAQ listing, a recent reverse stock split that brought the company's stock price to over $4 per share, and profitability potential are all factors that will contribute to MusclePharm's pivotal 2013.

Read full review and conclusion.

Meet the Athletes Who Trust Their Careers to MusclePharm Products


Read a series of diet, nutrition, training, other articles on the MusclePharm website

Watch our workout, interview, and industry news videos


Scientifically Advanced Research Protocol

Each and every product sold by MusclePharm® is the end result of a long development process involving leading nutrition scientists doctors, and top professional athletes in the country.

Step 1: The Vision

CEO, Brad Pyatt, President and fitness icon, Cory Gregory, and top sports nutritionist, Eric Serrano, MD take the first step by envisioning a new nutritional supplement with a specific set of performance properties

Step 2: The Formulation Process

Dr. Eric Serrano, the leading sports nutrition doctor in the US, who is the company's medical director and formulator, begins putting together several scientifically advanced - often breakthrough - combinations and ratios of ingredients resulting in superior formulations.

Step 3: Athlete Protocol Test

At the world reknown MP Performance Center, preliminary formulations of new products are tested on elite professional athletes. Product samples developed at the MP Performance Center are also given to athletes and strength coaches in the NFL, MMA, MLB, and other organizations for further analysis. MusclePharm is the first to use the field as it's lab, truly combining science with athletics. At our 30,000 sq. ft. training facility we use state-of-the-art technology like Omega Wave, DEXA, and Kaiser performance equipment to gather cutting-edge feedback about our formulations. Our medical advisory team, strength coaches, and top fitness experts evaluate the results to give us a practical read on the effectiveness of our products.

Step 4: Research and Product Testing

After athlete testing, the formulation is forwarded to Dr. Jeffrey Stout, a professor of exercise physiology at the University of Oklahoma, who performs an in-depth review of ingredient ratios and combinations to ensure it is sound from both a nutritional and health standpoint. Dr. Stout oversees clinical trials so that product claims are not based solely on published data from individual ingredients but from finished goods.

Step 5: Compliance and Safety

All products are checked against internationally published lists to ensure that no banned substances are included. All production runs are conducted in a state-of-the-art facility that follows government-approved Good Manufacturing Practices (cGMP). Before being made available to the public, all products are analytically verified for purity and verified for label claim accuracy to ensure that the information we put on the label is 100% accurate. Following testing, reference samples are kept so that we can hold our products to the highest quality assurance standards.


  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
MSLP
Current Price
Volume:
Bid Ask Day's Range
Wiki
MSLP News: Statement of Changes in Beneficial Ownership (4) 11/20/2014 04:52:17 PM
MSLP News: Statement of Changes in Beneficial Ownership (4) 11/20/2014 04:02:58 PM
MSLP News: Statement of Changes in Beneficial Ownership (4) 11/17/2014 04:44:19 PM
MSLP News: Current Report Filing (8-k) 11/14/2014 05:08:10 PM
MSLP News: Quarterly Report (10-q) 11/14/2014 04:39:42 PM
PostSubject
#70386  Sticky Note Arnold Schwarzenegger(TM) Iron Whey Now Available in Sam's basebalplayr33 10/08/14 08:36:37 AM
#70273  Sticky Note Walmart to Carry Two Arnold Schwarzenegger(TM) Series Nutritional drive929 10/02/14 08:38:06 AM
#67835  Sticky Note MusclePharm Strengthens Retail Presence with GNC turokman 06/24/14 08:02:10 AM
#66879  Sticky Note MusclePharm Receives Accolades in Brazil drive929 05/13/14 08:43:51 AM
#71504   The problem with Msclepharm is that they have codie 11/22/14 09:30:35 PM
#71503   I still don' understand why there aren't two TheExpertHimself 11/22/14 08:47:19 PM
#71502   Bs. Why you play the bible as if learning curve 11/22/14 05:20:34 AM
#71501   Don't say nithing..... learning curve 11/22/14 05:11:45 AM
#71500   allday, I have a comment for you. Please bellator_exec 11/21/14 11:22:40 PM
#71499   bb33, There is a difference in returns being first bellator_exec 11/21/14 11:14:16 PM
#71498   That's the interesting thing about bellator. He doesn't learning curve 11/21/14 07:59:33 PM
#71497   Bellator, Maybe I'll change it to PatsNbelichick, will that Alldaymnvikes 11/21/14 06:02:22 PM
#71496   You see bellator, I use all the information Alldaymnvikes 11/21/14 05:58:22 PM
#71495   Even with your "massive short" position here, short basebalplayr33 11/21/14 05:50:03 PM
#71493   Bellator, Sounds good. Just curious. Thanks. Alldaymnvikes 11/21/14 05:14:19 PM
#71491   Do you think Bell writes the script and learning curve 11/21/14 03:56:52 PM
#71490   Bellator, IF the pps of MSLP rises back to Alldaymnvikes 11/21/14 03:06:22 PM
#71489   I made a double at COCP; sold on learning curve 11/21/14 03:04:58 PM
#71488   Expert, But after reading this regarding Dr. Frost and Ebola bellator_exec 11/21/14 01:59:25 PM
#71487   Is Musclepharm getting closer to a cure against HIV? TheExpertHimself 11/21/14 01:48:21 PM
#71486   Hmmm....read the top section of comments. Sound familiar? bellator_exec 11/21/14 01:42:31 PM
#71485   Musclepharm lacks business ethics as much as it TheExpertHimself 11/21/14 01:15:56 PM
#71484   Thank you Turok. I read the transcript of bajista 11/21/14 12:52:45 PM
#71483   You are probably right about this. The insiders TheExpertHimself 11/21/14 12:50:20 PM
#71482   Expert, Insiders often make these nominal purchases to show bellator_exec 11/21/14 12:24:49 PM
#71481   it is kind of ridiculous when insiders buy TheExpertHimself 11/21/14 12:18:53 PM
#71480   You are the kind of long term investor TheExpertHimself 11/21/14 11:56:25 AM
#71479   Brad Pyatt should be the development manager...I think TheExpertHimself 11/21/14 11:36:59 AM
#71478   Debatable, as my cost basis is just over basebalplayr33 11/21/14 11:36:27 AM
#71476   He is obviously not an investor and his basebalplayr33 11/21/14 11:32:07 AM
#71475   Did Dick get his free Colin Kaepernick style bellator_exec 11/21/14 11:26:29 AM
#71474   Interview with Dick Huebner on MSLP: basebalplayr33 11/21/14 11:22:22 AM
#71473   SORRY, WRONG BOARD johncon 11/21/14 11:14:15 AM
#71472   wrong stock skippy! TheExpertHimself 11/21/14 11:12:40 AM
#71470   Another Frost convertible is all but assured. bellator_exec 11/21/14 11:09:03 AM
#71468   okay, fair enough. TheExpertHimself 11/21/14 10:55:13 AM
#71467   insider stock purchases can be explained by many TheExpertHimself 11/21/14 10:34:10 AM
#71466   I'm just a common shareholder who thinks the basebalplayr33 11/21/14 10:29:30 AM
#71464   for Brad: TheExpertHimself 11/21/14 09:53:51 AM
#71463   LOL - they successfully gave it away. Like codie 11/21/14 09:35:02 AM
#71462   Tiger Woods attitude is like he owns the TheExpertHimself 11/21/14 08:36:05 AM
#71461   talk about unnecessary dilution, 450,000 shares to Tiger....like TheExpertHimself 11/21/14 08:31:28 AM
#71460   God, Tiger Woods is just such a bore! TheExpertHimself 11/21/14 08:26:05 AM
#71459   revenues are not coming in around $60 million...$50 TheExpertHimself 11/21/14 08:06:17 AM
#71458   What's the book? learning curve 11/21/14 12:11:41 AM
#71457   I'm personally not particularly concerned about the company's TheExpertHimself 11/20/14 10:56:19 PM
#71456   Combat crunch has been so unsuccessful (sarcasm) that basebalplayr33 11/20/14 08:51:38 PM
#71455   probably some frostie company creation is the landlord...im TheExpertHimself 11/20/14 06:56:54 PM
#71454   Isn't that a rental as well? I bellator_exec 11/20/14 06:37:54 PM
#71453   and the Biozone manufacturing assets, what's up with TheExpertHimself 11/20/14 06:33:04 PM
#71452   Expert, Just a rental office with gym (that everyone bellator_exec 11/20/14 06:21:36 PM
#71451   oh, i forgot....Musclepharm doesn't really have any relevant operations TheExpertHimself 11/20/14 06:15:34 PM
#71450   if things don't improve by next conference call, TheExpertHimself 11/20/14 06:14:20 PM
#71449   introducing stock options would add further to expenses.....in TheExpertHimself 11/20/14 06:00:04 PM
PostSubject